Top

Published in:

01-02-2013 | Neurology and Preclinical Neurological Studies - CONy Pro/Con debate

Steroids in bacterial meningitis: yes

Authors: Felix Benninger, Israel Steiner

Published in: Journal of Neural Transmission | Issue 2/2013

Abstract

Bacterial meningitis is an infectious condition associated with severe morbidity and mortality, even with rapid diagnosis and appropriate antibiotic therapy. Despite decrease in the rate of bacterial meningitis brought about by vaccination programs against Haemophilus influenzae type-B and Streptococcus pneumonia, the incidence of meningitis is still unacceptably high and acute treatment remains the mainstay of therapy. The infection is accompanied by intense inflammatory response, which may carry deleterious effects upon the tissue. This led to the possibility of adjuvant corticosteroid therapy, as an anti-inflammatory agent, in bacterial meningitis. The debate focuses on the rational and evidence supporting and refuting such an approach.

Brouwer MC, McIntyre P, de Gans J, Prasad K, van de Beek D (2010) Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 9:CD004405PubMed

Czock D, Keller F, Rasche FM, Häussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61–98PubMedCrossRef

Daza P, Banda R, Misoya K, Katsulukuta A, Gessner BD, Katsande R, Mhlanga BR, Mueller JE, Nelson CB, Phiri A, Molyneux EM, Molyneux ME (2006) The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 24:6232–6239PubMedCrossRef

de Gans J (2002) Dexamethasone in adults with bacterial meningitis. N Engl J Med 347:1549–1556PubMedCrossRef

Fitch MT, Silver J (2008) CNS injury, glial scars, and inflammation: inhibitory extracellular matrices and regeneration failure. Exp Neurol 209:294–301PubMedCrossRef

Fitch MT, Doller C, Combs CK, Landreth GE, Silver J (1999) Cellular and molecular mechanisms of glial scarring and progressive cavitation: in vivo and in vitroanalysis of inflammation-induced secondary injury after CNS trauma. J Neurosci 19:8182–8198PubMed

Gross HP, Verner JV, Weller JM (1956) Pneumococcal meningitis treated with hydrocortisone, ACTH, and antibiotics. Med Bull (Ann Arbor) 22:329–331

Hoh TK, Mong CT (1962) The treatment of purulent meningitis with adrenal cortico-steroids. Singapore Med J 3:73–77PubMed

Kalita J, Misra UK, Ranjan P (2007) Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis. Eur J Neurol 14:33–37PubMedCrossRef

Kastenbauer S (2006) Pneumococcal meningitis: a 21st century perspective. Lancet Neurol 5:104–105PubMedCrossRef

Koedel U, Scheld WM, Pfister H-W (2002) Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2:721–736PubMedCrossRef

Koedel U, Klein M, Pfister H-W (2010a) New understandings on the pathophysiology of bacterial meningitis. Curr Opin Infect Dis 23:217–223PubMedCrossRef

Koedel U, Klein M, Pfister H-W (2010b) Modulation of brain injury as a target of adjunctive therapy in bacterial meningitis. Curr Infect Dis Rep 12:266–273PubMedCrossRef

Liu L, Johnson H, Cousens S (2012) Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379:2151–2161PubMedCrossRef

Lutsar I (2003) Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis. J Antimicrob Chemother 52:651–655PubMedCrossRef

Mai N, Chau T, Thwaites G (2007) Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. Clin Infect Dis 49(9):1387–1392

McIntyre PB, Berkey CS, King SM, Schaad UB, Kilpi T, Kanra GY, Perez CM (1997) Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 278:925–931PubMedCrossRef

Molyneux E, Walsh A, Forsyth H, Tembo M (2002) Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet 360(9328):211–218PubMedCrossRef

Mustafa MM, Ramilo O, Mertsola J, Risser RC, Beutler B, Hansen EJ, McCracken GH (1989) Modulation of inflammation and cachectin activity in relation to treatment of experimental Hemophilus influenzae type b meningitis. J Infect Dis 160:818–825PubMedCrossRef

Nau R, Soto A, Brück W (1999) Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J Neuropathol Exp Neurol 58:265–274PubMedCrossRef

Ozen M, Kanra G, Kara A, Bakar EE, Ceyhan M, Secmeer G, Cengiz AB (2006) Long-term beneficial effects of dexamethasone on intellectual and neuropsychological outcome of children with pneumococcal meningitis. Scand J Infect Dis 38:104–109PubMedCrossRef

Peltola H (2000) Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13:302–317PubMedCrossRef

Quagliarello VJ, Scheld WM (1997) Treatment of bacterial meningitis. N Engl J Med 336:708–716PubMedCrossRef

Ribble JC, Braude AI (1958) ACTH and adrenal steroids in the treatment of pneumococcal meningitis in adults. Am J Med 24:68–79PubMedCrossRef

Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, Cerami A, Tuomanen E (1990) The role of cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis. J Exp Med 171:439–448PubMedCrossRef

Scheld W, Koedel U, Nathan B (2002) Pathophysiology of bacterial meningitis: mechanism (s) of neuronal injury. J Infect Dis 186(Suppl 2):S225–S233PubMedCrossRef

Schneider O, Michel U, Zysk G, Dubuis O, Nau R (1999) Clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations. Neurology 53:1584–1587PubMedCrossRef

Sharief MK, Ciardi M, Thompson EJ (1992) Blood-brain barrier damage in patients with bacterial meningitis: association with tumor necrosis factor-alpha but not interleukin-1 beta. J Infect Dis 166:350–358PubMedCrossRef

Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold A, Bennett NM, Craig AS, Schaffner W, Thomas A, Lewis MM, Scallan E, Schuchat A, Emerging Infections Programs Network (2011) Bacterial meningitis in the United States, 1998–2007. N Engl J Med 364:2016–2025PubMedCrossRef

van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M (2004) Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 352(9):950

Van Furth A, Roord J (1996) Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. Infect Immun 64(12):4883–4890PubMed

Weber JR, Tuomanen EI (2007) Cellular damage in bacterial meningitis: an interplay of bacterial and host driven toxicity. J Neuroimmunol 184:45–52PubMedCrossRef

Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J (2006) Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol 5:123–129PubMedCrossRef

Title: Steroids in bacterial meningitis: yes
Authors: Felix Benninger
Israel Steiner
Publication date: 01-02-2013
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 2/2013
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-012-0938-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Steroids in bacterial meningitis: yes

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Anticoagulants versus antiplatelets for carotid artery dissection

Long-term decrease in immediate early gene expression after electroconvulsive seizures

Controversies in neurology, Vienna, 2012: Steroids in bacterial meningitis: no

Evaluation of speech impairment in early stages of Parkinson’s disease: a prospective study with the role of pharmacotherapy

Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations

Why antiplatelet treatment in spontaneous internal carotid dissection?